Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.


Company Announcement

When a company announces a recall, market withdrawal, or safety alert, the FDA posts the company's announcement as a public service. FDA does not endorse either the product or the company.

Premiere Sales Group Issues Voluntary Nationwide Recall of All Lots of Rhino 7 3000 and Rhino 7 Platinum 3000 Capsules due to Undeclared Active Pharmaceutical Ingredients

For Immediate Release

October 28, 2015







Premiere Sales Group of Santa Clarita, California is voluntarily recalling the following product to the consumer level: RHINO 7 3000 capsules packaged in a bottle containing six (6) capsules UPC: 616453150126 ALL LOT NUMBERS WITHIN EXPIRY and Rhino 7 Platinum 3000 Capsules packaged in a single (1) blister packs hang card count UPC: 700729253748 ALL LOT NUMBERS WITHIN EXPIRY. Lot numbers are on the back top right of the (1) count and on the side of the (6) count bottle.  FDA analysis found these products to contain undeclared desmethyl carbondenafil and dapoxetine.  Desmethyl carbondenafil is a phosphodiesterase PDE-5 inhibitor which is a class of drugs used to treat male erectile dysfunction, making these products unapproved new drugs.  Dapoxetine is an active ingredient not approved by the U.S. Food and Drug Administration (FDA).

Desmethyl carbondenafil may pose a threat to consumers because this PDE-5 inhibitor may interact with nitrates found in some prescription drugs (such as nitroglycerin) and may lower blood pressure to dangerous levels that can be life threatening.  Consumers with diabetes, high blood pressure, high cholesterol, or heart disease often take nitrates.

Dapoxetine has not been approved by the FDA and therefore its safety or efficacy has not been established. Chemically, dapoxetine belongs to a class of drugs known as selective serotonin reuptake inhibitors (SSRIs) used to treat depression.  Studies have shown that antidepressants increased the risk of suicidal thinking and behavior in children, adolescents, and young adults when compared to placebo. Therefore, consuming these products presents a health risk which could be life threatening.

Premiere Sales has not received a report of any adverse events associated with these products.

These products are marketed as dietary supplements for sexual enhancement and packaged in (6) count bottle and (1) count hanging card and distributed to consumers nationwide. Premiere Sales Group has discontinued sales of these products.

Premiere Sales Group has notified its customers of this voluntary recall via e-mail and phone.  Consumers that purchased these products from Premiere Sales Group should stop using them immediately and can return the products to : Premiere Sales Group, 21446 Golden Triangle Rd., Santa Clarita, CA 91350

Consumers with questions regarding this recall can contact Premiere Sales Group by telephone at 888-550-8621 between (Monday through Friday 7:30am to 4:00pm Pacific Standard Time Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using these products. Consumers can report adverse reactions or quality control problems to the FDA’s MedWatch Adverse Event Reporting program online, by regular mail, or by fax as follows:

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.


Product Photos

  • Rhino 7, 6 count
  • Rhino 7, front label
  • Rhino 7, back label

Page Last Updated: 10/28/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English